Helicobacter pylori protein-specific antibodies and risk of colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 1964-1974

  Epplein, Meira ^a,b   Pawlita, Michael ^d   Michel, Angelika ^d   Peek Jr , Richard M ^b   Cai, Qiuyin ^a   Blot, William J ^a,c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; HELICOBACTER PYLORI PROTEIN SPECIFIC ANTIBODY; UNCLASSIFIED DRUG; VACUOLATING TOXIN;

ADULT; AGED; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RECTUM CANCER; SEROPREVALENCE; SOCIAL STATUS;

ADULT; AGED; ANTIBODIES, BACTERIAL; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84887303331     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0702     Document Type: Article

References (41)

1. Zhao YS, Wang F, Chang D, Han B, You DY. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer. Int J Colorectal Dis 2008;23:875-82.
2. Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: A meta-analysis. Helicobacter 2006;11:75-80.
3. Konturek SJ, Konturek PC, Hartwich A, Hahn EG. Helicobacter pylori infection and gastrin and cyclooxygenase expression in gastric and colorectal malignancies. Regul Pept 2000;93:13-9.
4. Sobhani I, Lehy T, Laurent-Puig P, Cadiot G, Ruszniewski P, Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 1993; 105:22-30.
5. Burnett-Hartman AN, Newcomb PA, Potter JD. Infectious agents and colorectal cancer: A review of Helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus. Cancer Epidemiol Biomarkers Prev 2008;17:2970-9.
6. Peek RM Jr. Helicobacter pylori strain-specific modulation of gastric mucosal cellular turnover: implications for carcinogenesis. J Gastroenterol 2002;37 Suppl 13:10-6.
7. Eom BW, Lee HJ, Yoo MW, Cho JJ, Kim WH, Yang HK, et al. Synchronous and metachronous cancers in patients with gastric cancer. J Surg Oncol 2008;98:106-10.
8. Lee JH, Bae JS, Ryu KW, Lee JS, Park SR, Kim CG, et al. Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol 2006;12:2588-92.
9. Yoon SN, Oh ST, Lim SB, Kim TW, Kim JH, Yu CS, et al. Clinicopathologic characteristics of colorectal cancer patients with synchronous and metachronous gastric cancer. World J Surgery 2010; 34:2168-76.
10. Kan JY, Hsieh JS, Pan YS, Wang WM, Chen FM, Jan CM, et al. Clinical characteristics of patients with sporadic colorectal cancer and primary cancers of other organs. Kaohsiung J Med Sci 2006;22:547-53.
11. Blaser MJ. An endangered species in the stomach. Sci Am 2005;292: 38-45.
12. Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol 2012;175:441-50.
13. Limburg PJ, Stolzenberg-Solomon RZ, Colbert LH, Perez-Perez GI, Blaser MJ, Taylor PR, et al. Helicobacter pylori seropositivity and colorectal cancer risk: A prospective study of male smokers. Cancer Epidemiol Biomarkers Prev 2002;11:1095-9.
14. Shmuely H, Passaro D, Figer A, Niv Y, Pitlik S, Samra Z, et al. Relationship between Helicobacter pylori CagA status and colorectal cancer. Am J Gastroenterol 2001;96:3406-10.
15. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
16. Epplein M, Signorello LB, Zheng W, Peek RM Jr, Michel A, Williams SM, et al. Race, African ancestry, and Helicobacter pylori infection in a lowincome United States population. Cancer Epidemiol Biomarkers Prev 2011;20:826-34.
17. Signorello LB, Hargreaves MK, Steinwandel MD, Zheng W, Cai Q, Schlundt DG, et al. Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc 2005;97: 972-9.
18. Michel A, Waterboer T, Kist M, Pawlita M. Helicobacter pylori multiplex serology. Helicobacter 2009;14:525-35.
19. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, et al. Multiplex human papillomavirus serology based on in situpurified glutathione S-transferase fusion proteins. Clin Chem 2005;51: 1845-53.
20. Palframan SL, Kwok T, Gabriel K. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol 2012;2:92.
21. Salama NR, Otto G, Tompkins L, Falkow S. Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect Immun 2001;69:730-6.
22. Cover TL, Tummuru MK, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem 1994;269:10566-73.
23. Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P. New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res 2008;146:149-58.
24. Alvarez A, Ibiza S, Hernandez C, Alvarez-Barrientos A, Esplugues JV, Calatayud S. Gastrin induces leukocyte-endothelial cell interactions in vivo and contributes to the inflammation caused by Helicobacter pylori. FASEB J 2006;20:2396-8.
25. Brzozowski T, Konturek PC, Mierzwa M, Drozdowicz D, Bielanski W, Kwiecien S, et al. Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils. Helicobacter 2006;11:10-20.
26. Konturek PC, Brzozowski T, Konturek SJ, Kwiecien S, Pajdo R, Drozdowicz D, et al. Functional and morphological aspects of Helicobacter pylori-induced gastric cancer in Mongolian gerbils. Eur J Gastroenterol Hepatol 2003;15:745-54.
27. Gatta L, Di Mario F, Vaira D, Rugge M, Franze A, Plebani M, et al. Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2011;9: 440-2.
28. D'Onghia V, Leoncini R, Carli R, Santoro A, Giglioni S, Sorbellini F, et al. Circulating gastrin and ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI. Biomed Pharmacother 2007;61:137-41.
29. Strofilas A, Lagoudianakis EE, Seretis C, Pappas A, Koronakis N, Keramidaris D, et al. Association of Helicobacter pylori infection and colon cancer. J Clin Med Res 2012;4:172-6.
30. Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: A prospective study. Gastroenterology 1998;115:275-80.
31. Janulaityte-Gunther D, Kupcinskas L, Pavilonis A, Valuckas K, Wadstrom T, Andersen LP. Combined serum IgG response to Helicobacter pylori VacA and CagA predicts gastric cancer. FEMS Immunol Med Microbiol 2007;50:220-5.
32. Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfertheiner P. Anti-CagA and anti-VacA antibodies in Helicobacter pylori-infected patients with and without peptic ulcer disease in Serbia and Montenegro. Scand J Gastroenterol 2004;39:222-6.
33. Rudi J, Kolb C, Maiwald M, Zuna I, von Herbay A, Galle PR, et al. Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Dig Dis Sci 1997;42:1652-9.
34. Epplein M, Zheng W, Xiang YB, Peek RM Jr, Li H, Correa P, et al. Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev 2012;21: 2185-92.
35. Sezikli M, Guliter S, Apan TZ, Aksoy A, Keles H, Ozkurt ZN. Frequencies of serum antibodies to Helicobacter pylori CagA and VacA in a Turkish population with various gastroduodenal diseases. Int J Clin Pract 2006;60:1239-43.
36. Kuo CH, Wu DC, Lu CY, Su YC, Yu FJ, Lee YC, et al. Low molecular weight protein of Helicobacter pylori and its relation to gastroduodenal diseases. Hepato-gastroenterology 2003;50:897-901.
37. de Sablet T, Piazuelo MB, Shaffer CL, Schneider BG, Asim M, Chaturvedi R, et al. Phylogeographic origin of Helicobacter pylori is a determinant of gastric cancer risk. Gut 2011;60:1189-95.
38. Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 2009;44:239-48.
39. Sicinschi LA, Correa P, Peek RM, Camargo MC, Piazuelo MB, Romero- Gallo J, et al. CagA C-terminal variations in Helicobacter pylori strains from Colombian patients with gastric precancerous lesions. Clin Microbiol Infect 2010;16:369-78.
40. Argent RH, Thomas RJ, Letley DP, Rittig MG, Hardie KR, Atherton JC. Functional association between the Helicobacter pylori virulence factors VacA and CagA. J Med Microbiol 2008;57: 145-50.
41. Cardenas VM, Graham DY. Smoking and Helicobacter pylori infection in a sample of U.S. adults. Epidemiology 2005;16:586-90.